Helicobacter pylori vs coronary heart disease - searching for connections

Magdalena Chmiela1, Adrian Gajewski1, Karolina Rudnicka1

  • 1Magdalena Chmiela, Adrian Gajewski, Karolina Rudnicka, Department of Immunology and Infectious Biology, Faculty of Biology and Environmental Protection, University of Łódź, 90-236 Łódź, Poland.

Insights

Helicobacter pylori (H. pylori) infection may contribute to atherosclerosis and coronary heart disease (CHD) by triggering chronic inflammation. Further research is needed to determine if H. pylori initiates or accelerates plaque formation.

Area of Science:

  • Cardiovascular Medicine
  • Infectious Diseases
  • Gastroenterology

Background:

  • Helicobacter pylori (H. pylori) is a Gram-negative bacterium prevalent worldwide, often asymptomatic but linked to ulcers and gastric cancers.
  • Recent research suggests H. pylori may be associated with extragastric disorders, prompting investigation into its systemic effects.
  • Atherosclerosis and coronary heart disease (CHD) are multifactorial conditions where inflammation plays a key role.

Purpose of the Study:

  • To review and discuss the potential role of H. pylori infections in the development and progression of atherosclerosis and CHD.
  • To explore the hypothesis linking H. pylori infection to cardiovascular pathologies.
  • To synthesize current findings on the association between H. pylori and CHD.

Main Methods:

  • Literature review and synthesis of existing research findings.
  • Analysis of studies investigating the link between H. pylori prevalence and CHD occurrence.
  • Discussion of proposed mechanisms, particularly chronic inflammation.

Main Results:

  • Multiple studies indicate an indirect association between H. pylori prevalence and CHD.
  • The proposed mechanism involves H. pylori-induced chronic inflammation potentially facilitating CHD-related pathologies.
  • The exact role of H. pylori in initiating versus accelerating atheromatous plaque formation requires further elucidation.

Conclusions:

  • H. pylori infection is a potential contributing factor to atherosclerosis and CHD through chronic inflammation.
  • The widespread and often asymptomatic nature of H. pylori infections warrants consideration of its systemic impact.
  • Further investigation is crucial to clarify the causal relationship and timeline of H. pylori involvement in cardiovascular disease.

Related Concept Videos

Peptic Ulcer01:27

Peptic Ulcer

Peptic ulcers are erosive lesions of the gastric or duodenal lining, most commonly caused by Helicobacter pylori infection. This Gram-negative, helical bacterium has adapted to survive the stomach’s acidic environment by producing urease, which converts urea into ammonia and carbon dioxide. The ammonia neutralizes gastric acid in the bacterium’s immediate environment, allowing colonization of the gastric mucosa. H. pylori attaches to mucus-secreting epithelial cells, penetrates the...
33
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
1.1K
Pathophysiology of Peptic Ulcer Disease: Injurious Factors01:22

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
1.6K
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
2.3K
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
850
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
2.9K